The Raloxifene Use for The Heart (RUTH) trial explored the primary endpoints of coronary artery disease (CAD) and breast cancer in more than 10,000 women who had CAD or multiple risk factors for it. In the Study of Tamoxifen and Raloxifene (STAR) trial, postmenopausal women at increased risk of breast cancer received either oral tamoxifen (20 mg/day) or raloxifene (60 mg/day) over 5 years. The Raloxifene Use for The Heart (RUTH) study is an international, multicenter, randomized, double-blind, placebo-controlled clinical trial designed to enroll 10,000 patients. The 2 primary end points of the RUTH trial are coronary events and invasive breast cancer. The sample size was calculated using the methods of Lakatos The prospective, randomized, controlled RUTH study was begun when it was thought that raloxifene might confer some protection against heart disease, following results of an osteoporosis treatment. The Raloxifene Use for The Heart (RUTH) trial is an international, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate whether 60 mg/day of oral raloxifene compared with placebo reduces the risk of coronary events (coronary death, nonfatal myocardial infarction [MI], or hospitalized acute coronary syndromes. Rationale and overview of the Raloxifene Use for the Heart (RUTH) trial. Mosca L(1). Author information: (1)Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA. ljm10@columbia.edu Antiplatelet Therapy Use and the Risk of Venous Thromboembolic Events in the Raloxifene Use for the Heart (RUTH) Trial Article (PDF Available) in Journal of Women's Health 19(8):1459-65 · August. The raloxifene use for the heart (RUTH) trial was an international randomized, placebo-controlled trial that enrolled 10,101 postmenopausal women in two groups, one at high risk for coronary heart disease, and one with established coronary heart disease. Results from an international study of postmenopausal women in the Raloxifene Use for the Heart (RUTH) Trial. Circ Cardiovasc Qual Outcomes. 2013 Mar 1;6(2):164-70. doi: 10.1161/CIRCOUTCOMES.112.966986. Epub 2013 Mar 12. for the Raloxifene Use for The Heart (RUTH) Trial Investigators * Investigators participating in the RUTH trial are listed in the Appendix. Article.